High Vista Strategies LLC Macrogenics Inc Transaction History

High Vista Strategies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $438,577 - $912,802	-54,012 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $570,643 - $829,659	28,908 Added 115.15%	54,012 $1.13 Million
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $268,787 - $467,394	-13,118 Reduced 34.32%	25,104 $674,000
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $68,686 - $120,084	3,617 Added 10.45%	38,222 $1.22 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $319,508 - $427,986	16,461 Added 90.72%	34,605 $791,000
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $447,975 - $573,350	18,144 New	18,144 $457,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.